KTTA

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated neurofibromas, today announced that it will host a virtual key opinion leader (KOL) event, "Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas," on Wednesday, November 4, 2026, at 11:00 a.m. ET. The event will feature Rebecca M. Brown, MD, Associate Professor of Neurology at the University of Alabama at Birmingham (UAB), Heersink School of

-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over 500 days despite recurrent, metastatic melanoma carrying the BRAF V600E mutation and prior progression on targeted combination therapy with dabrafenib and trametinib. -- Long-Term Tolerability: Overall, the safety profile of PAS-004 in the heavily pre-treated advanced cancer population appears favorable. No Grade 3 treatment-related adverse events ("AEs"), no discontinuations due to treatment-related AEs, and no related serious AEs have been reported. Treatment-related AEs r

8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

25-NSE - Pasithea Therapeutics Corp. (0001841330) (Subject)

- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1)-associated neurofibromas, today announced it will presen

8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that management will participate in two investor conferences taking place in September 2026: the 12th Annu

8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

10-Q - Pasithea Therapeutics Corp. (0001841330) (Filer)

DEF 14A - Pasithea Therapeutics Corp. (0001841330) (Filer)

SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

PRE 14A - Pasithea Therapeutics Corp. (0001841330) (Filer)

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress’ standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that an ab

MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle & Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts. The Mind, Muscle & Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, ne

-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and gastrointestinal toxicities -- Protocol Amendment Extends Dose Escalation to Higher Levels: Continued dose escalation using tablet formulation to explore 18mg, 24mg, 30mg, 40mg, and up to 52mg dose levels to further characterize safety, pharmacokinetics (PK), and early efficacy signals at higher doses -- Potential Best-in-Class MEK Inhibitor Profile Emerging: Interim PK and safety data at pharmacologically active doses support PAS-004 as a diffe

SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 (NF1) patients with symptomatic inoperable, incompletely resected, or recurrent plexiform neurofibroma (PN). The amendments include an update to the dose escalation part of the study (Part A) to allow for the enrollment of ad

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in advance to schedule – MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it will participate as an exhibitor in the upcoming Children's Tumor Foundation (CTF) 2026 NF Conference, held June 26-30, 2026, in Denver, Colorado. "Direct engagement with the clinical and academic NF

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PAS-004 for the treatment of Amyotrophic Lateral Sclerosis (ALS). "ALS remains a devastating neurodegenerative disease with limited treatment options and significant unmet medical need," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "This designation further supports our efforts to explore the potential of PAS-004 in ALS and other serious diseases where

10-Q - Pasithea Therapeutics Corp. (0001841330) (Filer)

SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)